Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells

Guoyue Lu, Yahui Liu, Bai Ji, Feng Wei, Chunhai Hao, Guangyi Wang

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is currently under clinical development as a cancer therapeutic because it can induce apoptosis selectively in cancer cells. The vast majority of hepatocellular carcinomas (HCC), however, are resistant to TRAIL. In search of cancer therapeutics that can overcome TRAIL resistance, we show here that celecoxib and camptothecin can sensitize TRAIL-resistant HCC cell lines, HepG2 and Hep3B, to TRAIL-induced apoptosis through downregulation of cellular Fas-associated death domain-like interleukin-1β-converting enzyme-inhibitory protein (c-FLIP) and cleavage of caspase-8 and caspase-3 in the HCC cells. The study suggests a framework for TRAIL-based combination treatment of HCC.

Original languageEnglish (US)
Pages (from-to)629-634
Number of pages6
JournalCancer Investigation
Volume28
Issue number6
DOIs
StatePublished - Jun 2010
Externally publishedYes

Keywords

  • C-FLIP
  • Caspase-8
  • Celecoxib
  • Hepatocellular Carcinoma
  • TRAIL

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells'. Together they form a unique fingerprint.

  • Cite this